Placement on two elite stock screens and promising technical indicators put Ligand Pharmaceuticals (LGND) in focus. Ligand stock has landed a spot on the IBD 50 and the latest list of new buys by the best mutual funds. The monthly screen showed savvy money managers scooped over $248 million worth of Ligand stock in their latest reporting period. Further showcasing…